PMID- 32775432
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 
      Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
PG  - 6358954
LID - 10.1155/2020/6358954 [doi]
LID - 6358954
AB  - Gout is the most prevalent inflammatory arthritis in adults. Although the link 
      between gout and type 2 diabetes mellitus (T2DM) has been documented, our 
      understanding of the association between urate-lowering therapy (ULT) among gout 
      patients and T2DM development remains poor. We included 69,326 patients with 
      new-onset gout in 2000-2011. Each case was matched randomly with 1 patient 
      without gout during the study period, and 69,326 patients were recognized as the 
      comparison cohort. A Cox proportional hazard regression model was used to analyze 
      differences in the risk of T2DM development between patients with and without 
      gout after considering related comorbidities. After adjusting for potential 
      confounders, the case group had a higher risk of T2DM than the control cohort 
      (adjusted hazard ratio (aHR) = 1.30, 95%confidence interval (CI) = 1.24-1.38; P < 
      0.001). Gout patients without appropriate ULT had significantly higher risk of 
      T2DM development than the control cohort (aHR = 1.39; 95%CI = 1.30-1.48; P < 
      0.001). Among gout patients, those receiving ULT excluding probenecid (aHR = 
      0.80; 95%CI = 0.64-1.00), all had significantly lower risk of T2DM than gout 
      patients without ULT (all aHR < 0.90; all P < 0.001). In this study, we found 
      that gout increased the risk of T2DM; however, patients with any ULT exhibited a 
      lower risk of T2DM than gout patients without any ULT (all aHR < 0.90, P < 0.001; 
      excluding probenecid).
CI  - Copyright (c) 2020 Yi-Jen Fang et al.
FAU - Fang, Yi-Jen
AU  - Fang YJ
AD  - Research Center for Environmental Medicine, Kaohsiung Medical University, 
      Kaohsiung, Taiwan.
AD  - Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, 
      Kaohsiung Medical University and National Health Research Institutes, Taiwan.
AD  - Graduate Institute of Clinical Medicine, Department of Environmental Health, 
      Kaohsiung Medical University, Kaohsiung, Taiwan.
AD  - National Institute of Environmental Health Sciences, National Health Research 
      Institutes, Zhunan, Taiwan.
AD  - Digestive Disease Center, Show Chwan Memorial Hospital, Changhua, Taiwan.
FAU - Chung, Yun-Lung
AU  - Chung YL
AD  - Research Assistant Center, Show Chwan Health Care System, Changhua, Taiwan.
AD  - Department of Medical Research and Development, Chang Bing Show Chwan Memorial 
      Hospital, Changhua, Taiwan.
FAU - Lin, Cheng-Li
AU  - Lin CL
AUID- ORCID: 0000-0001-9926-3668
AD  - Management Office for Health Data, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Lim, Yun-Ping
AU  - Lim YP
AUID- ORCID: 0000-0001-9312-048X
AD  - Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Internal Medicine, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - Department of Medical Research, China Medical University Hospital, Taichung, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Gout Suppressants)
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - Aged
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*etiology/metabolism
MH  - Female
MH  - Gout/*complications/*drug therapy/metabolism
MH  - Gout Suppressants/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Uric Acid/*metabolism
PMC - PMC7407011
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/11 06:00
MHDA- 2021/04/23 06:00
PMCR- 2020/07/28
CRDT- 2020/08/11 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PHST- 2020/07/28 00:00 [pmc-release]
AID - 10.1155/2020/6358954 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Jul 28;2020:6358954. doi: 10.1155/2020/6358954. eCollection 
      2020.